Danish drug company Novo Nordisk faced criticism from the UK pharmaceutical regulator for failing to disclose approximately £7.8 million in payments to 150 recipients over three years. The company admitted to not reporting around 500 payments between 2020 and 2022, attributing the oversight to issues with their vendor tagging system. The Prescription Medicines Code of Practice Authority (PMCPA) oversees compliance with the Association of the British Pharmaceutical Industry’s code of practice, and Novo Nordisk’s failure to disclose payments to doctors, patients, journalists, and healthcare organizations has led to increased scrutiny and reprimand from the regulatory body.
Source link
Novo Nordisk failed to disclose £7.8m in payments to doctors and others over three years
